Literature DB >> 12895162

Health effects of kava use in an eastern Arnhem Land Aboriginal community.

A R Clough1, S P Jacups, Z Wang, C B Burns, R S Bailie, S J Cairney, A Collie, T Guyula, S P McDonald, B J Currie.   

Abstract

BACKGROUND: Heavy kava use in Aboriginal communities has been linked to various health effects, including anecdotes of sudden cardiac deaths. AIMS: To examine associations between kava use and potential health effects.
METHODS: A cross-sectional study was carried out within a kava-using east Arnhem Land Aboriginal community in tropical northern Australia. One-hundred-and-one adults who were current, recent or non-users of kava were enrolled in March 2000. Main outcome measures were physical, anthropometric, biochemical, haematological, immunological and neurocognitive assessments.
RESULTS: Kava users more frequently showed a characteristic dermopathy (P<0.001). They had increased levels of gamma-glutamyl transferase and alkaline phosphatase (P<0.001). Lymphocyte counts were significantly lower in kava users (P<0.001). Fibrinogen, plasminogen activator inhibitor-1 and neurocognitive tests were not different between kava use categories. IgE and IgG antibodies were elevated across the whole group, as were C-reactive protein and homocysteine.
CONCLUSIONS: Kava use was associated with dermopathy, liver function abnormalities and decreased lymphocytes. If kava continues to be used by Aboriginal populations, monitoring should focus on the health consequences of these findings, including a possible increase in serious infections. The interaction between kava, alcohol and other substances requires further study. Although markers of cardiovascular risk are increased across the population, these were not higher in kava users, and this increase may be linked to the large infectious pathogen burden reflective of the socioeconomic disadvantage seen in many remote Aboriginal communities.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12895162     DOI: 10.1046/j.1444-0903.2003.00405.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  7 in total

1.  Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited.

Authors:  Rolf Teschke; Jerome Sarris; Isaac Schweitzer
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

2.  The Current Use of Sakau (Kava) in Pohnpei Island, Federated States of Micronesia.

Authors:  Moeno Sakai; Minato Nakazawa
Journal:  Hawaii J Health Soc Welf       Date:  2022-07

3.  A re-evaluation of kava (Piper methysticum).

Authors:  E Ernst
Journal:  Br J Clin Pharmacol       Date:  2007-06-06       Impact factor: 4.335

4.  Toxicokinetics of kava.

Authors:  Anthony Rowe; Lillian Yuan Zhang; Iqbal Ramzan
Journal:  Adv Pharmacol Sci       Date:  2011-03-21

5.  Dietary feeding of Flavokawain A, a Kava chalcone, exhibits a satisfactory safety profile and its association with enhancement of phase II enzymes in mice.

Authors:  Xuesen Li; Xia Xu; Tao Ji; Zhongbo Liu; Mai Gu; Bang H Hoang; Xiaolin Zi
Journal:  Toxicol Rep       Date:  2014

Review 6.  Hepatotoxicity Induced by "the 3Ks": Kava, Kratom and Khat.

Authors:  Flaminia Pantano; Roberta Tittarelli; Giulio Mannocchi; Simona Zaami; Serafino Ricci; Raffaele Giorgetti; Daniela Terranova; Francesco P Busardò; Enrico Marinelli
Journal:  Int J Mol Sci       Date:  2016-04-16       Impact factor: 5.923

7.  Kava constituents exert selective anticancer effects in oral squamous cell carcinoma cells in vitro.

Authors:  Antonio Celentano; Callisthenis Yiannis; Rita Paolini; Pangzhen Zhang; Camile S Farah; Nicola Cirillo; Tami Yap; Michael McCullough
Journal:  Sci Rep       Date:  2020-09-28       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.